
Bill Anderson
CEO of Bayer AG since June 2023, formerly CEO of Genentech and Roche Pharmaceuticals.
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
Aug 12, 2026
Markets at Midyear: M&A, AI and What Comes Next
7:13
7:23
7:28
7:41

Bill AndersonGUEST
I think you have to think about what your view would be on a transaction and value and whatnot to be able to respond quickly because our disclosure rules are, are not great.

Bill AndersonGUEST
You know, you know, as far as for thirteen Ds, when accumulations that can happen through derivatives.

Bill AndersonGUEST
You may face a proposal to sell your company at a certain price, and it may go public, and your shareholders are gonna say, "Well, what do you think?" And you gotta-- You're not gonna tell them everything because you have to negotiate with the other side on value.

Bill AndersonGUEST
But there is an element of, you know, in the old days, when an activist would come, they would, you know, talk to you three or four times before you go public.
Reinventing Bayer: CEO Bill Anderson’s Push for Agility and Innovation
16:54

Bill AndersonGUEST
I saw really a high alignment of interests of kind of mission outlook and things.
24 MINS LATER